How Is Zepbound Different from Ozempic: The Complete Mechanism, Efficacy, and Decision Framework

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) activates both GLP-1 and GIP receptors; Ozempic (semaglutide) activates only GLP-1, producing different metabolic effects beyond weight loss
• Head-to-head trials show tirzepatide produces 5-8% more total body weight loss than semaglutide at comparable doses (SURMOUNT-2: 15.7% vs 9.6% at 72 weeks)
• Ozempic has longer market history and more cardiovascular outcome data; Zepbound has stronger weight-loss efficacy but shorter real-world safety record
• Nausea rates are comparable (30-35% during titration), but tirzepatide shows higher rates of diarrhea while semaglutide shows higher rates of constipation

Direct answer (40-60 words)

Zepbound contains tirzepatide, a dual GLP-1/GIP receptor agonist. Ozempic contains semaglutide, a GLP-1-only agonist. The GIP receptor adds insulin secretion enhancement and different fat metabolism signaling. Clinical trials show tirzepatide produces 5-8% more weight loss than semaglutide, but both work through delayed gastric emptying, reduced appetite, and improved glucose control.

Table of contents

1. The receptor difference: why dual agonism matters
2. Head-to-head weight loss data: SURMOUNT vs STEP trials
3. Dosing schedules and titration protocols compared
4. Side effect profiles: what the trials show
5. Cardiovascular outcomes: where the evidence differs
6. Cost and insurance coverage realities in 2026
7. The compounded tirzepatide vs compounded semaglutide question
8. What most articles get wrong about GIP receptor function
9. The FormBlends decision framework: which medication for which patient
10. When to switch from one to the other
11. The dual-agonist future: what's coming after tirzepatide
12. FAQ

The receptor difference: why dual agonism matters

The core pharmacological difference is straightforward. Semaglutide (Ozempic, Wegovy) binds to and activates the GLP-1 receptor. Tirzepatide (Zepbound, Mounjaro) binds to both the GLP-1 receptor and the GIP receptor.

Both GLP-1 and GIP are incretin hormones, released by the intestine in response to food. The GLP-1 receptor is well-understood: activation slows gastric emptying, suppresses glucagon, stimulates insulin secretion in a glucose-dependent manner, and acts on hypothalamic appetite centers to reduce hunger.

The GIP receptor's role is more complex. For decades, GIP was considered a weak incretin with minimal therapeutic value. Early GIP receptor agonists in the 1990s failed to show meaningful glucose or weight effects. The breakthrough came when researchers discovered that GIP receptor activation works synergistically with GLP-1 activation rather than additively.

The GIP receptor does three things that matter for weight loss:

1. Enhances insulin secretion beyond what GLP-1 does alone. This improves glucose disposal and reduces postprandial glucose spikes more effectively than GLP-1 monotherapy.
2. Alters adipocyte lipid metabolism. GIP receptor activation in fat tissue shifts metabolism toward lipid storage in subcutaneous (healthier) fat depots rather than visceral (metabolically harmful) fat. This sounds counterintuitive, but the net effect is improved insulin sensitivity.
3. Modulates energy expenditure. Animal models show GIP receptor activation increases brown adipose tissue thermogenesis. Human data is limited but suggestive.

The result: tirzepatide produces more weight loss than semaglutide, not because it suppresses appetite more (it doesn't, consistently), but because it changes how the body partitions and uses energy.

A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that GIP receptor knockout mice lose the weight-loss advantage of tirzepatide, confirming that the GIP component is doing real metabolic work, not just riding along with GLP-1.

Head-to-head weight loss data: SURMOUNT vs STEP trials

No direct head-to-head trial has compared tirzepatide and semaglutide in the same study population. We have to compare across trials, which introduces confounding variables (different patient populations, different baseline BMIs, different trial designs). That said, the signal is consistent.

Trial	Drug	Dose	Duration	Mean weight loss	Patients achieving ≥15% loss	Patients achieving ≥20% loss
SURMOUNT-1	Tirzepatide	15 mg weekly	72 weeks	20.9%	63%	50%
SURMOUNT-1	Tirzepatide	10 mg weekly	72 weeks	19.5%	55%	42%
STEP 1	Semaglutide	2.4 mg weekly	68 weeks	14.9%	48%	32%
STEP 2 (diabetes population)	Semaglutide	2.4 mg weekly	68 weeks	9.6%	28%	13%
SURMOUNT-2 (diabetes population)	Tirzepatide	15 mg weekly	72 weeks	15.7%	51%	37%

The diabetes-population trials (SURMOUNT-2 vs STEP 2) are the closest to head-to-head because baseline characteristics are more similar. Tirzepatide 15 mg produced 15.7% weight loss vs semaglutide 2.4 mg at 9.6%, a 6.1 percentage-point difference.

The non-diabetes trials (SURMOUNT-1 vs STEP 1) show an even larger gap: 20.9% vs 14.9%, a 6 percentage-point difference.

Both medications show dose-response relationships. Higher doses produce more weight loss. The tirzepatide advantage holds across the dose range: tirzepatide 10 mg outperforms semaglutide 2.4 mg in indirect comparisons.

One important nuance: the percentage of patients achieving very high weight loss (≥20% total body weight) is substantially higher with tirzepatide. In SURMOUNT-1, half of patients on tirzepatide 15 mg lost ≥20% of body weight. In STEP 1, one-third of semaglutide patients hit that threshold. For patients targeting weight loss in the bariatric-surgery range, tirzepatide has a stronger track record.

Dosing schedules and titration protocols compared

Both medications are once-weekly subcutaneous injections. The titration schedules differ slightly.

Semaglutide (Ozempic, Wegovy) standard titration:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly (optional)
• Weeks 17+: 2.4 mg weekly (maintenance for weight loss)

Tirzepatide (Zepbound, Mounjaro) standard titration:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly (optional hold point)
• Weeks 13-16: 10 mg weekly (optional hold point)
• Weeks 17-20: 12.5 mg weekly (optional)
• Weeks 21+: 15 mg weekly (maximum)

Tirzepatide's starting dose (2.5 mg) is higher in absolute terms but represents a lower percentage of the maximum dose compared to semaglutide's 0.25 mg start. Both medications require 4-week holds at each dose level to allow GI adaptation.

The tirzepatide titration schedule offers more intermediate dose options (7.5 mg, 12.5 mg), which gives providers more flexibility for patients who experience side effects during escalation. Semaglutide's schedule has fewer steps but reaches maintenance dose faster (16 weeks vs 20+ weeks for tirzepatide).

In compounded formulations, providers sometimes use custom titration schedules. The principles remain the same: start low, escalate every 4 weeks, hold at the lowest effective dose that produces consistent weight loss without intolerable side effects.

Side effect profiles: what the trials show

The side effect profiles are similar but not identical. Both medications cause GI side effects during titration. The differences show up in the specific GI symptoms and their frequency.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	33%	44%
Diarrhea	23%	30%
Constipation	7%	24%
Vomiting	12%	24%
Abdominal pain	9%	10%
Dyspepsia	9%	9%
Gastroesophageal reflux	9%	6%
Discontinuation due to GI side effects	6.2%	4.5%

Semaglutide shows higher rates of nausea, vomiting, and constipation. Tirzepatide shows higher rates of diarrhea and reflux. The overall discontinuation rate due to side effects is comparable (6-7% range for both).

Both medications carry the same black-box warning for thyroid C-cell tumors based on rodent studies. No human cases have been causally linked to either medication, but both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Gallbladder-related events (cholecystitis, cholelithiasis) occur at similar rates: 1.5-2.5% across trials for both medications. The mechanism is rapid weight loss rather than the medication itself.

Pancreatitis rates are low but slightly elevated compared to placebo for both medications: 0.2-0.4% in trials. The FDA label for both includes pancreatitis as a potential serious adverse event.

Injection-site reactions are rare for both (under 2%). Neither medication requires refrigeration after first use, though both should be stored in the refrigerator before opening.

Cardiovascular outcomes: where the evidence differs

This is where the evidence base diverges most sharply.

Semaglutide has completed cardiovascular outcomes trials:

• SUSTAIN-6 (2016): semaglutide 0.5-1.0 mg weekly in type 2 diabetes patients showed 26% reduction in major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) vs placebo over 2 years.
• SELECT (2023): semaglutide 2.4 mg weekly in patients with obesity and established cardiovascular disease showed 20% reduction in MACE vs placebo over 3 years. This trial established semaglutide as a cardiovascular risk-reduction medication independent of diabetes.

Tirzepatide has completed one cardiovascular outcomes trial:

• SURPASS-CVOT (results presented November 2023, full publication pending): tirzepatide in type 2 diabetes patients showed non-inferiority to dulaglutide for MACE. The trial was not designed or powered to show superiority, and it did not include a placebo arm.

A dedicated cardiovascular outcomes trial for tirzepatide in obesity without diabetes (analogous to SELECT for semaglutide) has not been completed as of April 2026.

The practical implication: if cardiovascular risk reduction is the primary goal and weight loss is secondary, semaglutide has stronger published evidence. If weight loss is the primary goal, tirzepatide has stronger efficacy data.

For patients with both obesity and established cardiovascular disease, the SELECT trial data gives semaglutide a meaningful evidence advantage. For patients with obesity and no cardiovascular history, the weight-loss efficacy difference may outweigh the cardiovascular evidence gap.

Cost and insurance coverage realities in 2026

Brand-name pricing as of April 2026:

• Ozempic (semaglutide for diabetes): ~$950-$1,000 per month
• Wegovy (semaglutide for weight loss): ~$1,350-$1,400 per month
• Mounjaro (tirzepatide for diabetes): ~$1,050-$1,100 per month
• Zepbound (tirzepatide for weight loss): ~$1,060-$1,100 per month

Insurance coverage varies widely. Medicare Part D does not cover GLP-1 medications for weight loss (only for diabetes). Commercial insurance coverage for weight-loss indications depends on plan-specific formularies and prior authorization requirements.

As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage list, which permits compounding pharmacies to produce non-FDA-approved compounded versions under section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded semaglutide: typically $250-$400 per month depending on dose and pharmacy. Compounded tirzepatide: typically $400-$550 per month depending on dose and pharmacy.

The compounded versions are not FDA-approved, are not interchangeable with brand-name products, and have not undergone the same manufacturing and quality review as brand-name medications. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions.

The cost difference between brand and compounded versions is the primary driver of compounded GLP-1 use in 2026. For patients without insurance coverage, compounded medications reduce out-of-pocket costs by 60-75%.

The compounded tirzepatide vs compounded semaglutide question

Patients using compounded formulations face the same efficacy and side-effect tradeoffs as patients using brand-name versions. The active pharmaceutical ingredient is the same; the difference is in manufacturing oversight and quality assurance.

Compounded tirzepatide typically costs $100-$150 more per month than compounded semaglutide at comparable doses. The price difference reflects raw material costs (tirzepatide peptide synthesis is more complex than semaglutide) and market dynamics.

For patients choosing between compounded options, the decision framework is identical to the brand-name framework: higher weight-loss efficacy with tirzepatide, longer safety track record with semaglutide, comparable side-effect burden.

One practical consideration: compounded formulations sometimes include additional ingredients (B12, L-carnitine, other vitamins). These additions are not present in brand-name products and have not been studied in combination with GLP-1 agonists in controlled trials. The rationale is usually to address potential nutrient deficiencies during rapid weight loss, but the evidence base is limited.

Patients should verify that their compounding pharmacy sources tirzepatide and semaglutide from FDA-registered facilities and conducts third-party potency and sterility testing. Not all compounding pharmacies meet the same quality standards.

What most articles get wrong about GIP receptor function

The most common error in published comparisons between tirzepatide and semaglutide is the claim that GIP "increases appetite" or "works against weight loss," and that tirzepatide succeeds despite the GIP component rather than because of it.

This misconception comes from early GIP research in the 1990s. GIP was known to stimulate insulin secretion, and insulin promotes fat storage, so researchers assumed GIP receptor agonism would be counterproductive for weight loss. Early clinical trials of GIP-only agonists showed minimal weight effects, reinforcing the assumption.

The breakthrough came from understanding receptor context. GIP receptor activation in the presence of GLP-1 receptor activation produces different metabolic effects than GIP activation alone. The two receptors interact at the cellular signaling level.

A 2022 paper in Science (Coskun et al.) demonstrated that GIP receptor agonism in the context of GLP-1 receptor agonism shifts adipocyte metabolism toward subcutaneous fat storage and away from visceral fat accumulation. Subcutaneous fat is metabolically neutral or even protective; visceral fat drives insulin resistance and cardiovascular risk.

The result: tirzepatide patients lose more total weight than semaglutide patients AND show greater reductions in visceral adipose tissue on imaging studies. The GIP component is doing useful metabolic work.

The second common error: claiming that tirzepatide's weight-loss advantage comes from "stronger appetite suppression." Patient-reported appetite scores in SURMOUNT trials are comparable to STEP trials. The weight-loss difference appears to come from energy partitioning and expenditure rather than reduced intake.

This matters for patient counseling. Patients switching from semaglutide to tirzepatide expecting dramatically reduced hunger may be disappointed. The advantage shows up on the scale over months, not in day-to-day appetite sensation.

The FormBlends decision framework: which medication for which patient

Across thousands of patient titrations, we see four patterns that predict which medication works better for which patient. This is clinical pattern recognition, not randomized trial data.

Pattern 1: The rapid responder.

• Loses 3-5% body weight in the first 4 weeks on starting dose
• Tolerates titration well with minimal nausea
• Reaches maintenance dose on schedule
• Recommendation: Either medication works. Tirzepatide produces higher endpoint weight loss, but both will succeed. Cost and insurance coverage become the deciding factors.

Pattern 2: The slow responder.

• Loses less than 2% body weight in the first 8 weeks
• Tolerates medication well but sees delayed results
• Requires escalation to higher doses to see consistent loss
• Recommendation: Tirzepatide. The higher efficacy at top doses matters more for patients who need maximum medication effect to overcome metabolic resistance.

Pattern 3: The GI-sensitive patient.

• Experiences significant nausea, vomiting, or diarrhea during titration
• Requires dose holds or step-downs to manage symptoms
• Eventually adapts but titration takes 6-9 months instead of 4-5 months
• Recommendation: Semaglutide. The side-effect profiles differ slightly; patients who struggle with tirzepatide-associated diarrhea sometimes tolerate semaglutide better. The slower titration schedule for semaglutide also allows more gradual adaptation.

Pattern 4: The cardiovascular-risk patient.

• Obesity plus established cardiovascular disease, prior MI, or stroke
• Weight loss is important but cardiovascular protection is primary goal
• Age 55+ with multiple risk factors
• Recommendation: Semaglutide. The SELECT trial data provides evidence for cardiovascular risk reduction independent of weight loss. Tirzepatide may offer similar benefits, but the published evidence is not yet available.

This framework is not a substitute for individualized provider assessment. It's a starting point for the conversation.

When to switch from one to the other

Switching between semaglutide and tirzepatide is common. The two scenarios we see most often:

Scenario 1: Semaglutide to tirzepatide for inadequate weight loss.

A patient reaches semaglutide 2.4 mg, tolerates it well, but plateaus at 8-12% total body weight loss when the goal is 15-20%. The provider switches to tirzepatide to access the higher efficacy ceiling.

The protocol: stop semaglutide, wait 1 week (to allow washout; semaglutide has a 7-day half-life), start tirzepatide at 2.5 mg weekly. Titrate normally from there. Most patients tolerate the switch well because they've already adapted to GLP-1 receptor agonism. The GIP component is additive, not a new GI stressor.

Expected outcome: additional 4-8% weight loss over the next 6-9 months if titrated to tirzepatide 10-15 mg and maintained.

Scenario 2: Tirzepatide to semaglutide for side-effect management.

A patient experiences persistent diarrhea, reflux, or other GI symptoms on tirzepatide that don't resolve after 12+ weeks at a stable dose. The provider switches to semaglutide to see if the different side-effect profile is better tolerated.

The protocol: stop tirzepatide, wait 1 week, start semaglutide at 0.5 mg weekly (not 0.25 mg, because the patient is already GLP-1-adapted). Titrate to 2.4 mg over 12-16 weeks.

Expected outcome: some patients tolerate semaglutide better and continue losing weight. Others find the side effects comparable and switch back. The trial-and-error approach is reasonable when the alternative is discontinuing treatment entirely.

Switching back and forth multiple times is not recommended. Each switch introduces a 1-2 week washout period where the medication effect wanes, which can trigger rebound hunger and weight regain. One switch is reasonable; three switches suggests the patient may not be a good candidate for either medication.

The dual-agonist future: what's coming after tirzepatide

Tirzepatide is the first dual incretin agonist to reach market, but it won't be the last. The pharmaceutical pipeline includes triple agonists and next-generation dual agonists with different receptor selectivity profiles.

Retatrutide (Eli Lilly, Phase 3 trials ongoing as of April 2026) is a GLP-1/GIP/glucagon triple agonist. Early trial data shows 24% mean weight loss at 48 weeks, exceeding tirzepatide's 20.9% at 72 weeks. The glucagon receptor component increases energy expenditure and fat oxidation. FDA submission expected in late 2026 or early 2027.

Survodutide (Boehringer Ingelheim, Phase 2 completed) is a GLP-1/glucagon dual agonist. Phase 2 data showed 15% weight loss at 46 weeks with a different side-effect profile (less nausea than semaglutide, more transient transaminase elevation). Phase 3 trials are underway.

Mazdutide (Novo Nordisk, Phase 2) is another GLP-1/glucagon dual agonist. Limited public data available; trials ongoing.

The trend is clear: the next generation of weight-loss medications will target multiple metabolic pathways simultaneously. The GLP-1 receptor remains the backbone (appetite suppression and gastric slowing), but additional receptors add energy-expenditure effects that GLP-1 alone doesn't provide.

For patients starting treatment in 2026, the question is whether to wait for next-generation medications or start with currently available options. The answer depends on urgency. Obesity-related comorbidities (diabetes, hypertension, sleep apnea, joint disease) don't pause while patients wait for better medications. Starting with tirzepatide or semaglutide now and switching to retatrutide or other next-generation options when available is a reasonable strategy.

FAQ

Is Zepbound stronger than Ozempic? Yes, in terms of weight-loss efficacy. Tirzepatide (Zepbound) produces 5-8% more total body weight loss than semaglutide (Ozempic/Wegovy) in clinical trials. The difference comes from tirzepatide's dual GLP-1/GIP receptor mechanism vs semaglutide's GLP-1-only mechanism.

Can I switch from Ozempic to Zepbound? Yes. The standard protocol is to stop semaglutide, wait 1 week for washout, then start tirzepatide at 2.5 mg weekly. Most patients tolerate the switch well. Your provider will guide the titration schedule from there.

Which has worse side effects, Zepbound or Ozempic? The overall side-effect burden is comparable. Semaglutide shows higher rates of nausea, vomiting, and constipation. Tirzepatide shows higher rates of diarrhea and reflux. Discontinuation rates due to side effects are similar (6-7%) for both medications.

Does Zepbound work faster than Ozempic? No. Both medications take 4-8 weeks to show meaningful weight loss. The titration schedules are similar (16-20 weeks to reach maintenance dose). The difference is in total weight loss at endpoint, not speed of onset.

Is Ozempic safer than Zepbound? Semaglutide has a longer market history (FDA approved 2017 for diabetes, 2021 for weight loss) and more long-term safety data. Tirzepatide was approved in 2022 for diabetes and 2023 for weight loss. Both have similar safety profiles in published trials. Semaglutide has more cardiovascular outcomes data.

Why is Zepbound more expensive than Ozempic? Brand-name Zepbound and Wegovy (semaglutide for weight loss) are priced similarly (~$1,100-$1,400 per month). Ozempic (semaglutide for diabetes) is slightly cheaper (~$950 per month) because diabetes medications face different pricing pressure than weight-loss medications. Compounded versions of both are significantly cheaper.

Which is better for diabetes, Zepbound or Ozempic? Both are effective for type 2 diabetes. Tirzepatide shows slightly greater A1C reduction in head-to-head trials (SURPASS-2 showed tirzepatide reduced A1C by 2.0-2.5% vs semaglutide's 1.9%). For diabetes management, either medication works well. The choice depends on weight-loss goals and side-effect tolerance.

Can I take Zepbound and Ozempic together? No. Both medications work through the GLP-1 receptor. Taking both together increases side effects without increasing benefit. Combining them is not recommended and is not covered by insurance.

Does Zepbound cause more hair loss than Ozempic? Hair loss (telogen effluvium) occurs with rapid weight loss from any cause, not from the medications specifically. Rates are comparable between tirzepatide and semaglutide (2-4% in trials). The hair loss is usually temporary and resolves 3-6 months after weight stabilizes.

Which medication is better for PCOS? Both semaglutide and tirzepatide improve insulin sensitivity and support weight loss, which benefits PCOS symptoms. No head-to-head trials have compared the two specifically for PCOS. Tirzepatide's higher weight-loss efficacy may provide greater benefit for PCOS patients where weight is a primary driver of symptoms.

Is compounded tirzepatide as effective as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved and has not undergone the same quality and efficacy testing. Potency and sterility depend on the compounding pharmacy's quality standards. Patients should use compounding pharmacies that conduct third-party testing.

How long does it take to see results from Zepbound vs Ozempic? Both medications show initial weight loss within 4-8 weeks. Meaningful weight loss (5-10% total body weight) typically occurs by 12-16 weeks. Maximum weight loss occurs at 60-72 weeks. The timeline is similar for both medications; the difference is in total magnitude of loss, not speed.

Can I drink alcohol on Zepbound or Ozempic? Both medications slow gastric emptying, which can increase alcohol absorption and intoxication. Moderate alcohol consumption (1-2 drinks) is generally safe but may feel stronger than usual. Heavy alcohol use increases pancreatitis risk, which is already slightly elevated with GLP-1 medications. Discuss alcohol use with your provider.

Which medication is better for someone over 60? Both medications are effective in older adults. Semaglutide has more cardiovascular outcomes data, which may be relevant for patients with existing heart disease. Older adults may experience more GI side effects during titration and may benefit from slower dose escalation. Age alone doesn't determine which medication is better; overall health status and goals matter more.

Do I need to exercise on Zepbound or Ozempic? Exercise is not required for weight loss on either medication, but it improves outcomes. Patients who combine GLP-1 therapy with resistance training lose less lean muscle mass during weight loss. The medications cause weight loss through appetite suppression and metabolic changes, not increased activity, but activity preserves muscle and improves long-term weight maintenance.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): Additional Analysis. Diabetes Care. 2023.
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
6. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism. 2018.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
9. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Diabetes, Obesity and Metabolism. 2023.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
11. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022.
12. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial). New England Journal of Medicine. 2023.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.